Personalis (NASDAQ:PSNL) Announces Earnings Results

Personalis (NASDAQ:PSNL) issued its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.05, FiscalAI reports. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported explosive clinical growth—6,183 tests in Q4 (329% YoY) and >16,000 tests in 2025—and announced Medicare coverage for breast and lung surveillance while guiding to 43,000–45,000 tests in 2026 and $78–80M in revenue.
• Biopharma MRD revenue is accelerating (≈240% YoY growth in 2025) as the company shifts from lower‑value legacy projects to higher‑value, multi‑year MRD partnerships, with MRD/pharma revenue guided to $20–21M in 2026.
• Margins and profitability will be pressured near term—gross margin compressed to 11% in Q4 and 22.7% for 2025, 2026 gross margin guide is 15–20%, and management expects a ~<$105M net loss and ~$100M cash burn in 2026 despite a $240M cash balance.
• Product innovation continued with the launch of the opt‑in Real‑Time Variant Tracker, now in an early access program, designed to detect therapy‑targetable and resistance mutations during MRD surveillance and potentially increase clinical utility and physician stickiness.

Personalis Stock Performance

NASDAQ:PSNL traded up $0.72 during mid-day trading on Thursday, hitting $9.03. The stock had a trading volume of 1,492,475 shares, compared to its average volume of 1,115,608. Personalis has a twelve month low of $2.83 and a twelve month high of $11.50. The stock has a market cap of $801.86 million, a price-to-earnings ratio of -10.26 and a beta of 1.98. The company’s 50 day simple moving average is $8.82 and its 200 day simple moving average is $7.93.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. BTIG Research increased their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Needham & Company LLC lifted their target price on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Guggenheim upped their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, HC Wainwright raised their price target on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.86.

Institutional Trading of Personalis

A number of hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Personalis in the second quarter valued at about $30,000. BNP Paribas Financial Markets raised its stake in Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after purchasing an additional 3,592 shares in the last quarter. Focus Partners Wealth bought a new stake in Personalis in the 1st quarter valued at about $47,000. Finally, AQR Capital Management LLC acquired a new position in shares of Personalis during the 4th quarter worth approximately $82,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.